Substance use in clinical high risk for psychosis: A review of the literature

Early Intervention in Psychiatry

Volumn 8, Issue 2, 2014, Pages 104-112

  Addington, Jean ^a   Case, Nevicia ^a   Saleem, Majid M ^a   Auther, Andrea M ^b   Cornblatt, Barbara A ^b,c   Cadenhead, Kristin S ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cannabis; Clinical high risk; Psychosis; Review; Substance use

Indexed keywords

ALCOHOL; AMPHETAMINE; AMPHETAMINE DERIVATIVE; BARBITURIC ACID DERIVATIVE; CANNABIS; COCAINE; HYPNOTIC AGENT; NICOTINE; OPIATE; PSYCHEDELIC AGENT;

ALCOHOL CONSUMPTION; ALGORITHM; CANNABIS USE; HUMAN; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SUBSTANCE ABUSE; SUBSTANCE USE; TOBACCO; COMPLICATION; DRUG USE; PRODROMAL SYMPTOM; PSYCHOLOGY; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS;

DRUG USERS; HUMANS; PREVALENCE; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 84898891640     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12100     Document Type: Review

References (63)

1. Regier DA, Farmer ME, Rae DS etal. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518.
2. Sevy S, Robinson DG, Solloway S etal. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 2001; 104: 367-374.
3. Wade D, Harrigan S, Whelan G, Burgess P, McGorry P. The impact of substance use disorders on clinical outcome in first episode psychosis. Schizophr Res 2004; 67 (Suppl. 1): B172.
4. Barnett JH, Werners U, Secher SM etal. Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 2007; 190: 515-520.
5. Strakowski SM, Tohen M, Stoll AL etal. Comorbidity in psychosis at first hospitalization. Am J Psychiatry 1993; 150: 752-757.
6. Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996; 40: 1-9.
7. Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L, Miller A, Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 1997; 23: 195-201.
8. Rabinowitz J, Bromet EJ, Lavelle J, Carlson G, Kovasznay B, Schwartz JE. Prevalence and severity of substance use disorder and onset of psychosis in first-admission psychotic patients. Psychol Med 1998; 28: 1411-1419.
9. Cantwell R, Brewin J, Glazebrook C etal. Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry 1999; 174: 150-153.
10. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 69-72.
11. Kamali M, McTigue O, Whitty P etal. Lifetime history of substance misuse in first episode psychosis: prevalence and its influence on psychopathology and onset of psychotic symptoms. Early Interv Psychiatry 2009; 3: 198-203.
12. Mazzoncini R, Donoghue K, Hart J etal. Illicit substance use and its correlates in first episode psychosis. Acta Psychiatr Scand 2010; 121: 351-358.
13. Bartels S, Teague G, Drake R, Clark R, Bush PW, Noordsy DL. Substance abuse in schizophrenia: service utilization and costs. J Nerv Ment Dis 1993; 181: 227-232.
14. Haywood T, Kravitz H, Grossman L, Cavanaugh J, Davis J, Lewis D. Predicting the 'revolving door' phenomenon amoung patients with schizophrenic schizoaffective, and affective disorders. Am J Psychiatry 1995; 152: 856-860.
15. Owen R, Fischer E, Booth B, Cuffel B. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996; 46: 853-858.
16. Lambert M, Conus P, Lubman DI etal. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005; 112: 141-148.
17. Miller BJ. A review of secong generation antipsychotic discontinuation in first episode psychosis. J Psychiatr Pract 2008; 14: 289-300.
18. Malla A, Norman R, Bechard-Evans L, Schmitz N, Manchanda R, Cassidy C. Factors influencing relapse during a 2 year follow up of first episode psychosis in a specialized early intervention service. Psychol Med 2008; 38: 1585-1593.
19. Lambert M, Naber D, Schacht A etal. Rates and predictors of remission and recovery during 3 years in 392 never treated patients with schizophrenia. Acta Psychiatr Scand 2008; 118: 220-229.
20. Callaghan RC, Cunningham JK, Allebeck P etal. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am J Psychiatry 2012; 169: 389-396.
21. Moore TH, Zammit S, Lingford-Hughes A etal. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370 (9584): 319-328.
22. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow up cohort study. BMJ 2011; 342: d738.
23. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110-117.
24. Fusar-Poli P, Bonoldi L, Yung A etal. Predicting psychosis: meta-analysis of transition outcomes in idividuals at high clinical risk. Arch Gen Psychiatry 2012; 69: 220-229.
25. McGlashan T, Walsh BC, Woods SW. The Psychosis Risk Syndrome: Handbook for Diagnosis and Follow-up. New York: Oxford University Press, 2010.
26. Yung AR, Yuen HP, McGorry PD etal. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry 2005; 39 (11-12): 964-971.
27. Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkotter J. Schizophrenia Proneness Instrument, Adult Version (SPI-A). Rome: Giovanni Fiorito Editore, 2007.
28. Schultze-Lutter F, Marshall M, Koch E. Schizophrenia Proneness Instrument: Child and Youth Version (SPI-CY), Extended English Translation. Rome: Giovanni Fiorito Editore, 2012.
29. Reicher-Rossler A, Aston J, Ventura J etal. The Basel Screening Instrument for Psychosis (BSIP): development, structure, reliability and validity (in German). Fortschr Neurol Psychiatr 2008; 76: 207-216.
30. Phillips LJ, Curry C, Yung AR, Yuen H, Adlard S, McGorry PD. Cannabis use is not associated with the development of psychosis in an 'ultra' high-risk group. Aust N Z J Psychiatry 2002; 36: 800-806.
31. Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 2007; 151 (1-2): 151-154.
32. Corcoran CM, Kimhy D, Stanford A etal. Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res 2008; 106 (2-3): 286-293.
33. Cannon TD, Cadenhead K, Cornblatt B etal. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65: 28-37.
34. Ruhrmann S, Schultze-Lutter F, Salokangas RK etal. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 2010; 67: 241-251.
35. Dragt S, Nieman DH, Schultze-Lutter F etal. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand 2012; 125: 45-53.
36. Auther AM, McLaughlin D, Carrion RE, Nagachandran P, Correll CU, Cornblatt BA. Prospective study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to psychosis and functional outcome. Psychol Med 2012; 42: 2485-2497.
37. Dragt S, Nieman DH, Becker HE etal. Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry 2010; 55: 165-171.
38. Korver N, Nieman DH, Becker HE etal. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. Aust N Z J Psychiatry 2010; 44: 230-236.
39. Thompson A, Nelson B, Yung A. Predictive validity of clinical variables in the 'at risk' for psychosis population: international comparison with results from the North American Prodrome Longitudinal Study. Schizophr Res 2011; 126 (1-3): 51-57.
40. van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MW, de Haan L. Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Curr Pharm Des 2012; 18: 5036-5044.
41. Koethe D, Giuffrida A, Schreiber D etal. Anandamine elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 2009; 194: 371-372.
42. First M, Spitzer RL, Gibbon M, Williams B, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition. New York: Biometrics Research Department, New York State Psychiatric Institute, 1995.
43. Andrews G, Peters L. The psychometeric properties of the Composite International Diagnostic Interview. Soc Psychiatry Psychiatr Epidemiol 1998; 33: 80-88.
44. Wing J, Babor T, Brugha T, Burke J. SCAN: schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry 1990; 47: 589-593.
45. Nurnberger JI Jr, Blehar MC, Kaufmann CA etal. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994; 51: 849-859.
46. Kaufman J, Birmaher B, Brent D etal. Schedule for affective disorders and schizophrenia for school aged children present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980-988.
47. Orvaschel HP-AJ. Schedule for affective disorders and schizophrenia for school-aged children - epidemiologic version. Fort Lauderdale, FL: Centre for Psychological Studies, Nova Southeastern University, 1994.
48. Dragt S, Nieman DH, Schultze-Lutter F etal. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatr Scand 2012; 125 (1): 45-53.
49. Barnes T, Mutsatsa S, Hutton SB, Watt H, Joyce E. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006; 188: 237-242.
50. Cooper J, Mancuso S, Borland R, Slade T, Galletly C, Castle D. Tobacco smoking among people living with a psychotic illness: the second Australian survey of psychosis. Aust N Z J Psychiatry 2012; 46: 851-863.
51. Leweke FM, Giuffrida A, Koethe D etal. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 2007; 94 (1-3): 29-36.
52. Galve-Roperh I, Palazuleous J, Aguado T, Guzman M. The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci 2009; 259: 371-382.
53. Koethe D, Hoyer C, Leweke FM. The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berl) 2009; 206: 551-561.
54. Fusar-Poli P, Borgwardt S, Bechdolf A etal. The psychosis high risk sate: a comprehensive state of the art review. JAMA Psychiatry 2013; 70: 107-120.
55. Caspi A, Moffitt TE, Cannon M etal. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57: 1117-1127.
56. Yucel M, Bora E, Lubman DI etal. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of exisiting findings and new data in a first episode sample. Schizophr Bull 2012; 38: 316-330.
57. Addington J, Cornblatt B, Cadenhead K etal. At clinical high risk for psychosis: outcome for non-converters. Am J Psychiatry 2011; 168 (8): 800-805.
58. Barkus E, Murray R. Substance use in adolescence and psychosis: clarifying the relationship. Annu Rev Clin Psychol 2010; 6: 365-389.
59. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. Lancet 1988; 1: 1000-1001.
60. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156: 319-327.
61. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325 (7374): 1199.
62. Henquet C, Krabbendam L, Spauwen J etal. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005; 330 (7481): 11.
63. Yung AR, Yuen HP, Berger G etal. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 2007; 33 (3): 673-681.